Imfinzi (Durvalumab)

Durvalumab is a monoclonal antibody that binds to the programmed death‑ligand 1 (PD‑L1) protein on tumor and immune cells. By blocking PD‑L1 from engaging its receptors PD‑1 and CD80, the drug lifts the inhibitory signal on T‑cells, restoring their ability to recognize and attack cancer cells.

The specific dose and schedule of Imfinzi are determined by the treating physician based on the approved indication, patient weight, and clinical condition. In practice, the product is supplied as a 500 mg vial that is reconstituted and administered intravenously according to the prescriber’s instructions.

Safety data for durvalumab in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To request Imfinzi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will ask for trade or institutional credentials. The sales team then provides pricing, availability, shipping details—including cold‑chain handling where required—and assists with any necessary import documentation.

Imfinzi (durvalumab) shares the same target as other PD‑L1 inhibitors such as atezolizumab and avelumab, but differences exist in dosing intervals, approved indications, and clinical trial outcomes. For example, durvalumab is uniquely approved as consolidation therapy after chemoradiation for stage III NSCLC, whereas atezolizumab has separate approvals for metastatic bladder cancer and first‑line NSCLC.

Imfinzi must be stored in a refrigerator at 2‑8 °C (36‑46 °F). Keep the vial in its original packaging, protect it from light, and do not freeze or shake. Once reconstituted, the solution should be used within the time frame specified in the product labeling and maintained under the same temperature conditions.

The powder is reconstituted with the supplied diluent to create a sterile solution for intravenous infusion. The prepared solution is administered by a healthcare professional, typically over 60 minutes, through an IV line. Administration settings follow standard aseptic techniques and monitoring for infusion‑related reactions.

The most serious immune‑mediated adverse events include pneumonitis (inflammation of lung tissue), hepatitis (liver inflammation), and endocrine disorders such as thyroiditis or adrenal insufficiency. These conditions can be severe or life‑threatening and require prompt medical evaluation, monitoring, and appropriate management, often including corticosteroid therapy.

Imfinzi is contraindicated in patients with known hypersensitivity to durvalumab or any of its excipients. Caution is advised for individuals with active autoimmune diseases, organ transplants, or those receiving systemic immunosuppressants, as the drug may exacerbate underlying conditions or increase the risk of graft rejection.